Glycogen synthase kinase-3 is required for optimal de novo synthesis of inositol

Molecular Microbiology

Volumn 63, Issue 4, 2007, Pages 1248-1258

  Azab, Abed N ^a   He, Quan ^a   Ju, Shulin ^a   Li, Guiling ^a   Greenberg, Miriam L ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INOSITOL; MACROPHAGE INFLAMMATORY PROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME SYNTHESIS; FUNGUS CULTURE; FUNGUS GROWTH; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; SEQUENCE HOMOLOGY; TEMPERATURE SENSITIVITY; WILD TYPE;

ENZYME INHIBITORS; GENE EXPRESSION REGULATION, FUNGAL; GLYCOGEN SYNTHASE KINASE 3; INOSITOL; MEMBRANE TRANSPORT PROTEINS; MUTATION; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; TEMPERATURE; THIADIAZOLES;

MAMMALIA; SACCHAROMYCES CEREVISIAE;

EID: 33846670518     PISSN: 0950382X     EISSN: 13652958     Source Type: Journal    
DOI: 10.1111/j.1365-2958.2007.05591.x     Document Type: Article

References (58)

1. Andoh, T., Hirata, Y., and Kikuchi, A. (2000) Yeast glycogen synthase kinase 3 is involved in protein degradation in cooperation with Bul1, Bul2, and Rsp5. Mol Cell Biol 20: 6712-6720.
2. Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., and Strul, K. (1994) Current Protocols in Molecular Biology, 13.12. New York: Wiley Interscience, John Wiley and Sons.
3. Barnett, J.E., Brice, R.E., and Corina, D.L. (1970) A colorimetric determination of inositol monophosphates as an assay for D-glucose 6-phosphate-1L-myoinositol 1-phosphate cyclase. Biochem J 119: 183-186.
4. Beckner, M.E., Gobbel, G.T., Abounader, R., Burovic, F., Agostino, N.R., Laterra, J., and Pollack, I.F. (2005) Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Lab Invest 85: 1457-1470.
5. Belmaker, R.H. (2004) Bipolar disorder. N Engl J Med 351: 476-486.
6. Belmaker, R.H., Bersudsky, Y., Agam, G., Levine, J., and Kofman, O. (1996) How does lithium work on manic depression? Clinical and psychological correlates of the inositol theory. Annu Rev Med 47: 47-56.
7. Berridge, M.J., and Irvine, R.F. (1989) Inositol phosphates and cell signaling. Nature 341: 197-204.
8. Berridge, M.J., Downes, C.P., and Hanley, M.R. (1982) Lithium amplifies agonist-dependent phophatidyl-inositol responses in brain and salivary glands. Biochem J 206: 587-595.
9. Bowden, C.L. (2004) Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry 65: 21-24.
10. Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
11. Brandish, P.E., Su, M., Holder, D.J., Hodor, P., Szumiloski, J., Kleinhanz, R.R., et al. (2005) Regulation of gene expression by lithium and depletion of inositol in slices of adult rat cortex. Neuron 45: 861-872.
12. Brex, P.A., Gomez-Anson, B., Parker, G.J., Molyneux, P.D., Miszkiel, K.A., Barker, G.J., et al. (1999) Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Sci 166: 16-22.
13. Carman, G.M., and Henry, S.A. (1999) Phospholipid biosynthesis in the yeast Saccharomyces cerevisiae and interrelationship with other metabolic processes. Prog Lipid Res 38: 361-399.
14. Chen, G., Haung, L.D., Jiang, Y.M., and Manji, H.K. (1999) The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72: 1327-1330.
15. Culbertson, M.R., Donahue, T.F., and Henry, S.A. (1976) Control of inositol biosynthesis in Saccharomyces cerevisiae: properties of a repressible enzyme system in extracts of wild-type (Ino+) cells. J Bacteriol 126: 232-242.
16. De Sarno, P., Li, X., and Jope, R.S. (2002) Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43: 1158-1164.
17. Dugo, L., Collin, M., Allen, D.A., Patel, N.S., Bauer, I., Mervaala, E.M., et al. (2005) GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 33: 1903-1912.
18. Gitlin, M. (2006) Treatment-resistant bipolar disorder. Mol Psychiatry 11: 227-240.
19. Gould, T.D., Quiroz, J.A., Singh, J., Zarate, C.A., Jr, and Manji, H.K. (2004a) Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 9: 734-755.
20. Gould, T.D., Einat, H., Bhat, R., and Manji, H.K. (2004b) AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 26: 1-4.
21. Gould, T.D., Zarate, C.A., and Manji, H.K. (2004c) Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry 65: 10-21.
22. Greenberg, M.L., and Lopes, J.M. (1996) Genetic regulation of phospholipids biosynthesis in Saccharomyces cerevisiae. Microbiol Rev 60: 1-20.
23. Grimes, C.A., and Jope, R.S. (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65: 391-426.
24. Hartman IV, J.L., Garvik, B., and Hartwell, L. (2001) Principles for the buffering of genetic variation. Science 291: 1001-1004.
25. Hirsch, J.P., and Henry, S.A. (1986) Expression of the Saccharomyces cerevisiae inositol-1-phosphate synthase (INO1) gene is regulated by factors that affect phospholipid synthesis. Mol Cell Biol 6: 3320-3328.
26. Jope, R.S. (2003) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24: 441-443.
27. Jope, R.S., and Johnson, G.V. (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biolog Sci 29: 95-102.
28. Ju, S., and Greenberg, M.L. (2003) Valproate disrupts regulation of inositol responsive genes and alters regulation of phospholipid biosynthesis. Mol Microbiol 49: 1595-1603.
29. Ju, S., and Greenberg, M.L. (2004) 1D-myo-inositol 3-phosphate synthase: conservation, regulation, and putative target of mood stabilizers. Clin Neurosci Res 4: 181-187.
30. Ju, S., Shaltiel, G., Shamir, A., Agam, G., and Greenberg, M.L. (2004) Human 1-D-myo-inositol-3-phosphate synthase is functional in yeast. J Biol Chem 279: 21759-21765.
31. Kaidanovich-Beilin, O., Milman, A., Weizman, A., Pick, C.G., and Eldar-Finkelman, H. (2004) Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 55: 781-784.
32. Kaliszewski, P., Ferreira, T., Gajewska, B., Szkopinska, A., Berges, T., and Zoladek, T. (2006) Enhanced levels of Pis1p (phosphatidylinositol synthase) improve the growth of Saccharomyces cerevisiae cells deficient in Rsp5 ubiquitin ligase. Biochem J 395: 173-181.
33. Kelley, M.J., Bailis, A.M., Henry, S.A., and Carman, G.M. (1988) Regulation of phospholipid biosynthesis in Saccharomyces cerevisiae by inositol. Inositol is an inhibitor of phosphatidylserine synthase activity. J Biol Chem 263: 18078-18085.
34. Kim, A.J., Shi, Y., Austin, R.C., and Werstuck, J.H. (2005) Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J Cell Sci 118: 89-99.
35. Klein, P.S., and Melton, D.A. (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93: 8455-8459.
36. Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J.A., Snyder, G.L., et al. (2001) Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 276: 251-260.
37. Loewus, M.W., Loewus, F.A., Brillinger, G.U., Otsuka, H., and Floss, H.G. (1980) Stereochemistry of the myo-inositol-1-phosphate synthase reaction. J Biol Chem 255: 11710-11712.
38. McLaurin, J., Franklin, T., Chakrabartty, A., and Fraser, P.E. (1998) Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. J Mol Biol 278: 183-194.
39. Martinez, A., Castro, A., Dorronsoro, I., and Alonso, M. (2002) Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 22: 373-384.
40. Maslanski, J.A., and Busa, W.B. (1990) A sensitive and specific mass assay for myo-inositol and inositol phosphates. In Methods in Inositide Research. Irvine, R.F. (ed.). New York: Raven Press, pp. 113-126.
41. Narrow, W.E., Rae, D.S., and Robins, L.N. (2002) Revised prevalence estimates of mental disorders in the United States: using clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 59: 115-123.
42. Nemeroff, C.B. (2003) Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry 64: 532-529.
43. Phiel, C.J., Zhang, F., Huang, E.Y., Guenther, M.G., Lazar, M.A., and Klein, P.S. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
44. Plyte, S.E., Hughes, K., Nikolakaki, E., Pulverer, B.J., and Woodgett, J.R. (1992) Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta 1114: 147-162.
45. Robinson, K.S., Lai, K., Cannon, T.A., and McGraw, P. (1996) Inositol transport in Saccharomyces cerevisiae is regulated by transcriptional and degradative endocytic mechanisms during the growth cycle that are distinct from inositol-induced regulation. Mol Biol Cell 7: 81-89.
46. Shaltiel, G., Shamir, A., Shapiro, J., Ding, D., Dalton, E., Bialer, M., et al. (2004) Valproate decreases inositol biosynthesis. Biol Psychiatry 56: 868-874.
47. Shears, S.B. (1989) Metabolism of the inositol phosphates produced upon receptor activation. Biochem J 260: 313-324.
48. Shetty, H.U., Holloway, H.W., Acevedo, L.D., and Galdzicki, Z. (1996) Brain accumulation of myo-inositol in the trisomy 16 mouse, an animal model of Down's syndrome. Biochem J 313: 31-33.
49. Shi, Y., Vaden, D.L., Ju, S., Ding, D., Geiger, J.H., and Greenberg, M.L. (2005) Genetic perturbation of glycolysis results in inhibition of de novo inositol biosynthesis. J Biol Chem 280: 41805-41810.
50. Stambolic, V., Ruel, L., and Woodgett, J.R. (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6: 1664-1668.
51. Vaden, D.L., Ding, D., Peterson, B., and Greenberg, M.L. (2001) Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J Biol Chem 276: 15466-15471.
52. Vaden, D.L., Gohil, V.M., Gu, Z., and Greenberg, M.L. (2005) Separation of yeast phospholipids using one-dimensional thin-layer chromatography. Anal Biochem 338: 162-164.
53. Werstuck, G.H., Kim, A.J., Brenstrum, T., Ohnmacht, S.A., Panna, E., and Capretta, A. (2004) Examining the correlations between GSK-3 inhibitory properties and anticonvulsant efficacy of valproate and valproate-related compounds. Bioorg Med Chem Lett 14: 5465-5467.
54. Whiting, P.H., Palmano, K.P., and Hawthorne, J.N. (1979) Enzymes of myo-inositol and inositol lipid metabolism in rats with streptozotocin-induced diabetes. Biochem J 179: 549-553.
55. Woodgett, J.R. (1990) Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9: 2431-2438.
56. Yaspo, M.L. (2001) Taking a functional genomic approach in molecular medicine. Trends Mol Med 7: 494-501.
57. Zhang, F., Phiel, C.J., Spece, L., Gurvich, N., and Klein, P.S. (2003) Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278: 33067-33077.
58. Zhong, Q., Gvozdenovic-Jeremic, J., Webster, P., Zhou, J., and Greenberg, M.L. (2005) Loss of function of KRE5 suppresses temperature sensitivity of mutants lacking mitochondrial anionic lipids. Mol Biol Cell 16: 665-675.